The short answer
TB-500's documented benefits are animal benefits. In rats and mice, the thymosin beta-4 (Tβ4) system it comes from accelerates skin wound closure, improves tendon healing, promotes new blood-vessel growth, and protects heart muscle after infarction. In humans, the fragment sold as TB-500 has no completed efficacy trial of any kind — its first registered human study, a phase 1/2 dose-escalation trial in 80 adults, only began recruiting in February 2026 (NCT07487363). Anything framed as a benefit below is a research finding, not an expected outcome for a person.
What the fragment itself does
Most "TB-500 benefits" lists are really thymosin beta-4 benefits lists. Two findings are specific to the seven-amino-acid actin-binding segment (LKKTETQ, residues 17–23) that vendors usually mean by TB-500:
It carries the angiogenic activity. Working with proteolytic fragments and synthetic peptides, researchers found the seven-amino-acid actin-binding motif is essential for Tβ4's angiogenic activity in endothelial migration and vessel-sprouting assays (Philp et al., FASEB J 2003).
It heals skin about as well as the parent molecule — in aged mice. The synthetic LKKTETQ seven-mer promoted dermal repair "comparable to that observed with the parent molecule" (Philp et al., Wound Repair Regen 2003).
That is a real, if narrow, basis for treating the fragment as biologically active rather than as an arbitrary offcut. What it does not establish is a dose, a route, or an effect size in people.
Tissue-repair evidence, by model
Tendon. In 32 rats with transected and surgically repaired Achilles tendons, TB-500 at 60 µg/kg/day intraperitoneally for four weeks produced a statistically significant increase in maximum load to failure versus controls, plus significantly better Bonar (P=0.016) and Movin (P=0.017) histology scores. BPC-157 at 10 µg/kg/day improved the same measures numerically without reaching significance, and combining the two added nothing (Biçer et al., Jt Dis Relat Surg 2026). This is the study most directly relevant to the recovery claims — and it is an exploratory four-week rat study.
Skin. Tβ4 increased reepithelialization of rat full-thickness wounds by 42% at four days and 61% at seven days, with greater wound contraction, collagen deposition, and angiogenesis; it stimulated keratinocyte migration 2–3-fold with as little as 10 pg added (Malinda et al., J Invest Dermatol 1999).
Heart. After coronary artery ligation in mice, Tβ4 upregulated integrin-linked kinase and Akt activity, improved early myocyte survival, and improved cardiac function (Bock-Marquette et al., Nature 2004). This result is why Tβ4 was later taken into cardiac clinical trials — with the full protein, given intravenously, in hospital.
What humans have actually shown
Thymosin beta-4 has been through real clinical development, and the results are mixed rather than triumphant. Phase 2 dermal wound programs in pressure ulcers (n=72) and venous stasis ulcers (n=72) completed (NCT00382174, NCT00832091), an epidermolysis bullosa study was terminated (NCT00311766), and in ophthalmology a phase 2 dry-eye trial missed both primary endpoints while hitting several secondary ones (Sosne & Ousler, Clin Ophthalmol 2015).
None of that involved a person injecting a milligram of LKKTETQ for a sore Achilles. The honest summary is that the parent protein has been credible enough to justify twenty years of trials, and has not yet won one outright.
Claims that have no support
Marketing for TB-500 — especially in the equine market, where regulators documented claims of muscle building, stopping bleeding, and raising red blood cell counts (RMTC Thymosin β4 Bulletin) — outruns the science by a wide margin. There is no human evidence for hypertrophy, endurance, hair growth, or "systemic rejuvenation" from this fragment, and no dose–response data in people for anything.
The same bulletin reports that when TB-500-labeled products were analyzed, most contained no peptide at all — so for many buyers the practical question is not what the molecule does but whether they received one.
Sport & Anti-Doping Warning
TB-500 (a thymosin beta-4 fragment) is classified as a prohibited peptide hormone/growth factor and has appeared in elite-sport doping investigations, including endurance running cases where it was used alongside EPO and other banned agents.
- >Overview of peptide hormones and growth factors on the WADA Prohibited List (S2)
- >Reporting on TB-500 and other experimental peptides in performance contexts
Use of TB-500 by athletes governed by anti-doping rules is generally treated as a serious violation, particularly when combined with other anabolic or blood-boosting drugs.